Physician profile
Jonathan S Warnelo
NPI 1467980854
$1,469.71
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $499 · 2021: $432 · 2022: $18.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $529.85 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $218.59 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $178.13 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $120.78 | 2019 | |
| Pfizer INC. | $120.56 | 2020 | |
| Sunovion Pharmaceuticals INC. | $120.10 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $117.19 | 2019 | |
| Genzyme Corporation | $23.16 | 2019 | |
| Mallinckrodt Enterprises LLC | $22.36 | 2019 | |
| Celgene Corporation | $18.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Warnelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.